focus -WSS

focus

author：knowledge 2025-09-06 08:39:44 - browse：81

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： European regulators consider appeal over Amylyx ALS drug

WSS

Cancer cells are shown to suck energy source from immune cells

Inside the rise of 'mukbang' eating videos

Takeaways from AdvaMed, the largest medical devices conference

Living organ donors deserve priority status for transplants

Humana CEO Bruce Broussard to step down in 2024

European regulators recommend Amylyx's ALS drug be rejected

entertainment

focus

explore

Medicare details structure of new drug price negotiation program

Humana CEO Bruce Broussard to step down in 2024

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Inside the rise of 'mukbang' eating videos

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Novo: Oral version of Ozempic leads to 15% weight loss

Jerome Adams on the need for new antivirals for Covid

Biogen nominates mother of director’s child to replace him on board

What does generative AI mean for health care? We asked experts

Humana CEO Bruce Broussard to step down in 2024

entertainment

How to fix the rural physician shortage in the U.S.

How to fix the rural physician shortage in the U.S.

How should state employee insurance handle Wegovy?

Living organ donors deserve priority status for transplants

What's changing in Medicare's open enrollment this year?

Millions may soon lose Medicaid when they don't have to

Wikipedia

leisure time

hotspot

Wikipedia